Top Stock Reports for Costco, Walt Disney & AstraZeneca

29.02.24 20:41 Uhr

Werte in diesem Artikel
Aktien

127,50 EUR -0,40 EUR -0,31%

672,20 EUR -4,50 EUR -0,66%

107,36 EUR 0,10 EUR 0,09%

Indizes

PKT PKT

37.799,0 PKT 63,9 PKT 0,17%

7.858,1 PKT 37,8 PKT 0,48%

4.280,2 PKT 19,8 PKT 0,47%

17.713,7 PKT 6,8 PKT 0,04%

15.865,3 PKT -19,8 PKT -0,12%

6.996,9 PKT -71,7 PKT -1,01%

14.855,4 PKT -28,9 PKT -0,19%

2.717,9 PKT 11,0 PKT 0,41%

2.491,8 PKT -31,6 PKT -1,25%

937,6 PKT -14,0 PKT -1,47%

2.397,8 PKT -3,5 PKT -0,14%

5.051,4 PKT -10,4 PKT -0,21%

4.345,2 PKT 18,2 PKT 0,42%

Thursday, February 29, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp. (COST), The Walt Disney Co. (DIS) and AstraZeneca PLC (AZN). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Costco’s shares have outperformed the Zacks Retail - Discount Stores industry over the past year (+60.9% vs. +30.8%). A consumer defensive stock, Costco has been surviving the market turmoil pretty well.The discount retailer’s key strengths are strategic investments, a customer-centric approach, merchandise initiatives and an emphasis on membership growth. These factors have been helping it register decent sales and earnings numbers.This outlook reflects Costco’s ability to navigate the challenging operating environment, generate solid sales and register high membership renewal rates. A favorable product mix, steady store traffic, pricing power and strong liquidity position should help Costco keep outperforming. While trading at a premium to its peers, its long-term growth prospects should help the stock see solid upside.(You can read the full research report on Costco here >>>)Shares of Walt Disney have outperformed the Zacks Media Conglomerates industry over the past year (+12.8% vs. +1.2%). The company’s first-quarter fiscal 2024 results reflect a solid revival in international theme park and resort businesses. Recent attractions like the Frozen theme land at Hong Kong Disneyland and Walt Disney Park in Paris, as well as the Zootopia theme land at Shanghai Disney, are expected to boost the prospects of the theme park business.Disney’s declining ad revenues, due to fewer impressions, has been a headwind for some time now. Disney+’s profitability is expected to be negatively impacted by higher investments in content, which will increase programming and production costs at Media and Entertainment Distribution.Its leveraged balance sheet remains a concern. Disney+ is facing tough competition in the streaming market from the likes of Netflix and Amazon Prime Video.(You can read the full research report on Walt Disney here >>>)AstraZeneca shares of have gained +2.4% over the past year against the Zacks Large Cap Pharmaceuticals industry’s gain of +35.3%. The company’s key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra and Farxiga should keep driving revenues.  AstraZeneca has also been engaged in external acquisitions and strategic collaborations to boost its pipeline, while investing in geographic areas of high growth like emerging markets. Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period.However, AstraZeneca’s diabetes franchise faces stiff competition, while pricing pressure hurts sales in the respiratory unit. Sales have slowed down in its key market, China. Estimates have gone up slightly ahead of the Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters.(You can read the full research report on AstraZeneca here >>>)Other noteworthy reports we are featuring today include O'Reilly Automotive, Inc. (ORLY), Restaurant Brands International Inc. (QSR) and Arch Capital Group Ltd. (ACGL).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadDecent Comparable Sales Run to Fuel Costco's (COST) Top LineImprovement In Resorts & Park Businesses Aids Disney (DIS)Key Drugs Aid AstraZeneca (AZN) Sales; Pipeline StrongFeatured ReportsRising Store Count to Aid O'Reilly (ORLY), High Capex AilsThe Zacks analyst is optimistic about O'Reilly's plan to open 190-200 stores in 2024, which is set to fuel sales. However, high capex to develop advanced superior offerings might limit its cash flows.Restaurant Brands (QSR) Banks on Unit Expansion, Costs HighPer the Zacks analyst, Restaurant Brands is likely to benefit from unit growth, strong digital ordering and a healthy balance of check-in traffic. However, elevated cost pressures is a headwind.Product Diversification, Rate Hike Aid Arch Capital (ACGL)Per the Zacks analyst, Arch Capital is set to grow on rate increases and growth in existing accounts. Global operations and compelling product portfolio provides diversification and earnings stabilityBiogen's (BIIB) New Drugs Skyclarys & Others Can Revive GrowthThe Zacks analyst believes Biogen's new products like Leqembi for Alzheimer's disease, Skyclarys for Friedreich's ataxia and Zurzuvae for depression can help revive growth in the long termOmnicom (OMC) Gains From Diversification Amid Low LiquidityPer the Zacks analyst, Omnicom has a diversified business, with service offerings across areas of functional expertise and geographical regions. Low liquidity is concerning.Digital Transformation and Acquisitions Aid Amdocs (DOX)Per the Zacks analyst, Amdocs is benefiting from ongoing digital transformations and adoption of its cloud services. Moreover, strategic acquisitions like Astadia and Openet are a positive.APA Corporation (APA) to Gain from Suriname PortfolioThe Zacks analyst believes that APA's significant drilling success in Suriname points to significant cash flow potential but is worried about the oil explorer's high debt burden.New UpgradesOrganic Growth & Solid AUM Support T. Rowe Price (TROW)Per the Zacks analyst, solid AUM balance, broadening distribution reach and business diversification efforts aid T. Rowe Price's top-line. Solid liquidity aids sustainable capital distributions.Strong Demand for IVL Aids ShockWave Medical's (SWAV) GrowthPer the Zacks analyst, sustained clinical acceptance and penetration of IVL is promising for ShockWave Medical. The fiscal 2023 results were driven by strength across the entire Shockwave franchise.AMERISAFE (AMSF) Benefits From Policy Retention & No DebtPer the Zacks analyst, AMERISAFE's strong policy retention, prudent investments and solid financial position with no debt will produce favorable returns to investors.New DowngradesFluctuating Commodity Price, Competition Ail Murphy (MUR)Per the Zacks analyst Murphy Oil future prospects can be adversely impacted by the fluctuating commodity prices, while competitive industry can affect its profitability.Lower Fertilizer Prices, High Debt Ail Nutrien (NTR)Per the Zacks analyst, lower fertilizer prices partly due to weaker demand will weigh on the company's bottom line. Its high debt level also poses a concern.Higher Costs and Stiff Competition To Hurt Ciena (CIEN)Per the Zacks analyst, Ciena's performance is affected by increasing research and development to fend off stiff competition are headwinds. Also, the leveraged balance sheet is a concern.Top 5 ChatGPT Stocks RevealedZacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”Download Free ChatGPT Stock Report Right Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report O'Reilly Automotive, Inc. (ORLY): Free Stock Analysis Report Costco Wholesale Corporation (COST): Free Stock Analysis Report The Walt Disney Company (DIS): Free Stock Analysis Report Arch Capital Group Ltd. (ACGL): Free Stock Analysis Report Restaurant Brands International Inc. (QSR): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf AstraZeneca

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf AstraZeneca

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu Walt Disney

Analysen zu Walt Disney

DatumRatingAnalyst
27.03.2024Walt Disney BuyUBS AG
08.01.2024Walt Disney BuyUBS AG
05.09.2023Walt Disney OverweightJP Morgan Chase & Co.
11.05.2023Walt Disney OverweightJP Morgan Chase & Co.
09.02.2023Walt Disney OutperformCredit Suisse Group
DatumRatingAnalyst
27.03.2024Walt Disney BuyUBS AG
08.01.2024Walt Disney BuyUBS AG
05.09.2023Walt Disney OverweightJP Morgan Chase & Co.
11.05.2023Walt Disney OverweightJP Morgan Chase & Co.
09.02.2023Walt Disney OutperformCredit Suisse Group
DatumRatingAnalyst
09.11.2022Walt Disney Equal WeightBarclays Capital
14.05.2021Walt Disney market-performBernstein Research
19.04.2021Walt Disney market-performBernstein Research
12.02.2021Walt Disney market-performBernstein Research
13.10.2020Walt Disney Sector PerformRBC Capital Markets
DatumRatingAnalyst
18.06.2018Walt Disney SellPivotal Research Group
09.01.2018Walt Disney SellPivotal Research Group
14.12.2017Walt Disney SellPivotal Research Group
20.01.2017Walt Disney UnderperformBMO Capital Markets
12.01.2017Walt Disney SellPivotal Research Group

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Walt Disney nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"